CBD Science Group PLC
cbdsciencegroup.co.uk/invest/
eis
Investment to date:
£98,539
Share price:
£0.50

target amount:
£2,000,000
£400,000
Tab
here10EIS Only
Offer Information
Min Max
Investment Target £400,000 £2,000,000
Share Price £0.50 £0.50
Shares Offered info 800,000 4,000,000
Percentage Offered info 3.85% 16.67%
Shares Issued info 20,000,000
Pre-money Valuation £10,000,000
Share Type Ordinary
Minimum Investment £100.00
Tax Relief Available EIS
Sector Healthcare & Pharmaceuticals
Location London, United Kingdom
Company Number 11845112
Pitch Launched On 15/09/2021
Pitch Closes On 14/11/2021
Accepted Payment Methods
Payment Methods
CBD Science Group PLC
CBD Science Group will research, develop and make commercially effective, plant-based, cannabinoid medicines available as a treatment for patients suffering from cancer-related pain. The company is raising up to £2 million to support the financing of working capital and clinical trials, due to commence in Q2 2022.
About CBD Science Group PLC

CBD Science Group seeks to help cancer patients with chronic pain. At present, there are an estimated 3 million people suffering from cancer in the UK, with 1,000 new patients diagnosed daily. 33% of those who suffer from cancer pain are currently undertreated. For patients that do not have medical contraindications, current treatments are ineffective and inflict severe side effects. These are patients already in a vulnerable condition suffering greatly. The opioid epidemic is fast becoming a serious cause for concern in the UK. Opioid painkillers are seen to induce side effects such as nausea, drowsiness, muscular pain and anxiety. Their addictive nature is causing repeated misuse and ultimately have been shown to trigger substance use disorders (SUD). Plant-based cannabinoid medicines present a real solution to this real issue and provide a great opportunity to deliver a safe and effective pain treatment for those with urgent and unmet needs.

CBD Science Group has identified this unmet medical need and has initiated Real-World Evidence (RWE) clinical trials.

 Unmet Medical Needs in the UK

 

CBD Science Group has launched its RWE trial

Under the guidance of a leading Clinical Advisory Board, overseen by former NHS Deputy Medical Director, Professor Mike Bewick, the company will launch its Real World Evidence (RWE) trial. Under the trial, evidence will be gathered on cancer patients suffering from chronic pain where current treatments are ineffective. Patient-level clinical evidence will be used to assess the value of treatments based on real health outcomes in the Real World setting.

The clinical trial will take place over 3-4 months, after which NHS Hospital Trusts are obligated to pay for ongoing treatments, with anticipated annual revenues of £3.6 million for every 1,000 patients. The estimated patient pool is greater than 650,000 patients in the UK, with patient recruitment for the trial commencing in Q4 2021. Confirmed hospital research centres include Royal Marsden Trust (Europe’s Leading Cancer Centre), Birmingham, Manchester, Belfast and Leeds. Promising discussions with Glasgow, Cardiff, St Thomas & Guys and Nottingham are ongoing as CBD Science seeks to further expand operations across the UK.

Furthermore, highly sought-after endorsements have been received from a number of key industry bodies, including, the National Cancer Research Institute (NCRI), the Medicines and Healthcare product Regulatory Agency (MHRA),  Northwest EHealth (NWEH), and the Royal Marsden Trust.

Adopting Innovative Technologies to Enhance Patient Care through Data Collection

A suite of modern technologies, including smartwatches, will support CBD Science with capturing data in clinical settings and beyond. This will include an implementation of immediate diagnostic algorithms that will help to alleviate suffering, while also monitoring positive and adverse effects on a patient by patient basis.

Utilising Technology in the medical world

Market Opportunity

Medicinal cannabis has been legal in the UK since November 2018. The market is large and growing, with Prohibition Partners estimating a total medicinal cannabis market value of £7.7 billion by 2028. A number of companies are already seeing success in this new market, including the largest UK based cannabinoid company, GW Pharma, which was recently acquired by Jazz Pharmaceuticals for £5.3 billion.

 Projected Market Value by 2028

 

Endorsements and Strategic Relationships

The company has received support from a number of Key Stakeholders including:

MHRA – Medicines Healthcare Regulatory Agency

CPRD – Clinical Practice Research Database

NWEH – North-West EHealth

NIHR – National Institute for Health Research

NCRI – National Cancer Research Institute

• Royal Marsden Hospital Trust Committed
Endorsements and Strategic relationships

 

 

Revenue from Patient Usage for CBD Science Group PLC

Expected Annual Revenue per Patient: £3,650   

Revenue matrix for CBD Science Group

Revenue Stats




To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below

Join
Log in


Why join Crowd for Angels?

arrowRegister in minutes

arrowNo fees for Investors

arrowInvest from £25

arrowAccess your portfolio 24/7

Why invest in UK businesses

Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.


About Crowd for Angels

With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.

Management Team



To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below

Join
Log in


Why join Crowd for Angels?

arrowRegister in minutes

arrowNo fees for Investors

arrowInvest from £25

arrowAccess your portfolio 24/7

Why invest in UK businesses

Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.


About Crowd for Angels

With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.

Documents



To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below

Join
Log in


Why join Crowd for Angels?

arrowRegister in minutes

arrowNo fees for Investors

arrowInvest from £25

arrowAccess your portfolio 24/7

Why invest in UK businesses

Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.


About Crowd for Angels

With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.

Updates



To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below

Join
Log in


Why join Crowd for Angels?

arrowRegister in minutes

arrowNo fees for Investors

arrowInvest from £25

arrowAccess your portfolio 24/7

Why invest in UK businesses

Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.


About Crowd for Angels

With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.

Rewards



To find out more about this pitch or to ask the Director(s) a question please Join Now or Log in below

Join
Log in


Why join Crowd for Angels?

arrowRegister in minutes

arrowNo fees for Investors

arrowInvest from £25

arrowAccess your portfolio 24/7

Why invest in UK businesses

Discover investment opportunities, support companies you believe in and share their success Take advantage of SEIS/EIS tax relief to minimize your tax and the opportunity to obtain high-interest rates.


About Crowd for Angels

With us, you can gain access to great UK companies offering Shares, Crowd Bonds or Digitalised Assets through our easy to use online platform.

Offer Information
Min Max
Investment Target £400,000 £2,000,000
Share Price £0.50 £0.50
Shares Offered info 800,000 4,000,000
Percentage Offered info 3.85% 16.67%
Shares Issued info 20,000,000
Pre-money Valuation £10,000,000
Share Type Ordinary
Minimum Investment £100.00
Tax Relief Available EIS
Sector Healthcare & Pharmaceuticals
Location London, United Kingdom
Company Number 11845112
Pitch Launched On 15/09/2021
Pitch Closes On 14/11/2021
Accepted Payment Methods
Payment Methods

To read the full CBD Science Group PLC pitch, please join.
It is free, quick and easy.

Join Now

Already registered? Log in

Risk Warning

Investing in small public listed or private companies involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Investing in debt pitches through Crowd for Angels (UK) Limited involves lending to companies and therefore your capital is at risk and interest payments are not guaranteed if the borrower defaults. Investments on this website are targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own Investment Decisions. You will only be able to invest in pitches on this website once you are authorised. Please click here to read the full Risk Warning.

This page has been approved as a Financial Promotion by Crowd for Angels (UK) Limited (Company number: 03064807) , which is authorised and regulated by the Financial Conduct Authority (Reference number: 176508). Investments can only be made on the basis of information provided in the Pitches by the Investee Companies concerned. Crowd for Angels takes no responsibility for this Information or for any recommendations or opinions made by the Investee Companies.

Pitches may contain forward looking statements and financial forecasts or projections. Forecasts are not a reliable indicator of future performance. Crowd For Angels makes no judgement or opinion of the likelihood of targets being achieved. Investments made in companies listed on the Crowd For Angels platform are not covered by the Financial Services Compensation Scheme (FSCS).

The availability of any tax relief, including EIS and SEIS, depends on the individual circumstances of each investor and of the company concerned, and may be subject to change in the future. If you are in any doubt about the availability of any tax reliefs, or the tax treatment of your investment, you should obtain independent tax advice before proceeding with your investment.